Publications by authors named "Manutsanun Inthawong"
[This corrects the article DOI: 10.1371/journal.pntd.
View Article and Find Full Text PDFArticle Synopsis
- This study looks at how to measure T cell responses in the blood using a special method that combines two techniques called intracellular cytokine staining and flow cytometry.* -
- By using whole blood instead of just certain types of cells, researchers can get better results without needing to process the sample right away, which is great for patients who are kids, elderly, or very sick.* -
- The researchers created a new test that can find specific T cells that respond to infections, like scrub typhus, making it easier for scientists to study immune responses in places with limited resources.*
Background: Scrub typhus is a vector-borne febrile illness caused by Orientia tsutsugamushi transmitted by the bite of Trombiculid mites. O. tsutsugamushi has a high genetic diversity and is increasingly recognized to have a wider global distribution than previously assumed.
View Article and Find Full Text PDFCoronavirus disease 2019 (COVID-19) is an acute respiratory illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The prevention of SARS-CoV-2 transmission has become a global priority. Previously, we showed that a protein subunit vaccine that was developed based on the fusion of the SARS-CoV-2 receptor-binding domain (RBD) to the Fc portion of human IgG1 (RBD-Fc), produced in Nicotiana benthamiana, and adjuvanted with alum, namely, Baiya SARS-CoV-2 Vax 1, induced potent immunological responses in both mice and cynomolgus monkeys.
View Article and Find Full Text PDFArticle Synopsis
- Virus-like particles (VLPs) are non-infectious subunit vaccines made from viral proteins that can effectively trigger immune responses, making them a promising option for various diseases, including COVID-19.
- In this study, researchers developed a chimeric VLP COVID-19 vaccine using proteins from both the influenza virus and the SARS-CoV-2 virus, showing that these engineered particles elicit strong antibody responses in mice.
- After vaccination, mice experienced significantly reduced viral loads and improved survival rates when exposed to SARS-CoV-2, demonstrating the vaccine's potential effectiveness and a balanced immune response while keeping inflammation and brain lesions under control.